2+ -dependent actions of angiotensin II (AngII
Introduction
Angiotensin II (AngII) is among the most potent vasoactive substances produced in humans. Its effects are numerous, from vasoconstriction to control of fluid and electrolytes balances. Many of the physiological and pathological effects of AngII are mediated by the angiotensin II receptor type 1A (AT 1 R). Activation of AT 1 R triggers cardiovascular remodeling in subjects with hypertension and heart failure [19] . Pharmacological inhibition of AT 1 R has been exploited extensively in the treatment of hypertension and heart failure. Classically, AT 1 R is a 7-pass transmembrane receptor associated with Gα q/11 , whose dissociation upon AngII binding to AT 1 R is associated with increases in intracellular free Ca 2+ concentration, followed by both pregenomic actions such as contractions of the heart and muscle cells and genomic actions that alter the expression of various genes [17] . AT 1 R also interacts with β-arrestin, triggering a G protein-independent cascade of downstream events, with distinct physiological outcomes [11] . Additionally, the activities of AT 1 R are regulated by receptorinteracting proteins [1, 6, 32] . Nevertheless, aspects of signaling via AT 1 R at the receptor level and its regulatory inputs remain incompletely understood.
Calmodulin is a ubiquitous transducer of intracellular Ca 2+ signals.
It is estimated to bind up to 300 intracellular proteins [21] . Despite its universal requirement, CaM is not expressed sufficiently for all its binding sites within the cell [10] . Shortage of CaM relative to its binding sites [12, 14, 23, 24, 31] , coupled with disparate binding affinities for its target proteins from ∼10 −11 to 10 −5 M, has made CaM a target for dynamic competition among its binding proteins, leading to new modes of functional coupling in cells [23, 24] . Over the last two decades, CaM has been shown to interact with several GPCRs, such as the metabotropic glutamate receptors mGluR1 and mGluR5 [18] , opioid μ receptors [30] , the parathyroid hormone receptor 1 [15] , the 5-HT(1A) and 5-HT(2C) receptors [3, 28] , the D 2 dopamine receptors [7] , AT 1 R [22, 32] , and the G protein-coupled estrogen receptor 1 (GPER) [25, 27] . CaM binding to the 5-HT(1A) alters receptor phosphorylation and G protein coupling [28] ; while its association with 5-HT(2C) and GPER is important receptor-mediated ERK1/2 activation [3, 25] . In 1999, a CaM-binding domain was identified at the juxtamembranous region of the 4th submembrane domain (SMD4 JM ) of AT 1 R (a.a. 305 -327, rat sequence) [22] . The interaction was shown to be Ca 2+ -dependent. In 2013, Zhang et al. identified another CaMbinding domain on SMD3 (a.a. 215 -232) and confirmed the previously identified domain on the juxtamembranous domain of the 4th submembrane domain of the receptor [32] . In that work, CaM was shown to compete for G βγ association with both the partial SMD3 and SMD4 JM peptides in vitro, indicating a role for CaM binding in G βγ coupling.
Despite identification of two CaM-binding domains on AT 1 R, questions remain to be answered regarding total number of binding sites, biochemical properties and regulatory inputs of the interactions with CaM. Additionally, the functional impact of these interactions in cells are unknown. For example, are segments a.a. 305-327 (rat) in SMD4 JM [22] and a.a. 215-232 (rat sequence) in SMD3 [32] 
Materials and Methods

Materials
All molecular biology enzymes and competent cells were from New England Biolabs (Ipswich, MA). RNeasy kit was from Qiagen. High Capacity cDNA reverse transcription kit was from Applied Biosystems (Foster City, CA). Fetal bovine serum, isopropyl β-D-1-thiogalactopyranoside, and M-199 culture medium were obtained from Sigma-Aldrich (St. Louis, MO). HisPur cobalt resin was from Thermo Fisher (Waltham, MA). Phenyl Sepharose CL-4B resin was from GE Healthcare Life Sciences (Milwaukee, MI). DMEM culture medium was from Caisson Laboratories (Smithfield, UT). Polyethylenimine and penicillin/streptomycin were from ThermoFisher (Carlsbad, CA). Fura-2/AM was purchased from Teflabs (Austin, TX). Ionomycin, indo-1, XRhod-5F, collagenase type A, papain and dithiothreitol were obtained from ThermoFisher Scientific (Carlsbad, CA). Angiotensin II peptide, W-7 and losartan potassium were from Sigma Aldrich (St. Louis, MO). Pierce™ BCA protein assay kit, enhanced chemiluminescence detection kit, and Br2BAPTA were from ThermoScientific (Carlsbad, CA). Bovine serum albumin (BSA) was from Research Products International Corp. (Mt. Prospect, IL). Anti-β actin antibody was from ThermoScientific (RB9421P1). Anti-smooth muscle α actin antibody was from Abcam (ab5694, Cambridge, MA). Anti-ERK1/2 antibody was from Santa Cruz Biotechnology (SC514302, Santa Cruz, CA). Anti-phospho-p44/42 MAPK mouse monoclonal antibody (L34F12) and rabbit anti-hemagglutinin (HA, C29F4) antibody were obtained from Cell Signaling Technology (Danvers, MA).
Molecular biology
Total mRNA from HEK 293 cells was isolated using the RNeasy mini kit. Full-length human AT 1 R was reverse transcribed from this total mRNA at 100 ng/μL RNA using the High Capacity cDNA reverse transcription kit. To clone AT 1 R in frame, a BamHI restriction site was incorporated into the N-terminus of the receptor, while a stop codon followed by an XhoI restriction site was incorporated into its C-terminus. Primers for this reaction are listed in Table 1 . The BamHI-AT 1 RXhoI sequence was then cloned into a pcDNA3.1 mammalian expression vector downstream a hemagglutinin (HA) epitope tag as previously described [27] .
Constructs for FRET-based biosensors to screen for CaM binding domains in AT 1 R were generated as described previously for GPER [27] . Insert sequences from AT 1 R's submembrane domains or fragments thereof were PCR amplified from the full-length AT 1 R sequence, with incorporation of the KpnI and AgeI restriction sites to the N-and Cterminal ends of the sequences. The insert sequences were then substituted in frame in between the citrine EYFP (EYFP c )-ECFP pair of previously reported pET bacterial expression vectors that encode GPER Table 1  Primers. biosensors [25, 27] to generate biosensor for AT 1 R. As with previously described biosensors for GPER, we used the BSAT 1 R x nomenclature, where x denotes the amino acid sequence (human) of the AT 1 R fragment used as biosensor insert. Biosensors and primers are listed in Table 1 .
Substitutions in the submembrane domains of AT 1 R to reduce CaM binding were generated by incorporating gBlock gene fragments containing the desired sequence (IDTDNA, Coraville, IA) in frame into the full-length receptor. The SMD wild-type and mutant amino acid sequences are listed in Table 2 . Gblock gene fragments for the mutant sequences as well as restriction enzymes used to clone the mutant domains in frame to full-length AT 1 R are listed in Table 3 . Mutant biosensors were subsequently generated by PCR amplifying SMD sequences from the full-length mutant AT 1 R, followed by incorporation of these sequences in between the EYFP c -ECFP pair as described above. Primers to generate the mutant inserts are listed in Table 1 .
To generate fusions between mKate2 and wild-type or mutant AT 1 R, mKate2 was PCR amplified from the pDONR-P4-P1-mKate2 plasmid, a gift from Dr. Planas, Institut d'Investigacions Biomediques de Barcelona (Addgene.org). The KpnI and BamHI restriction sites were incorporated into the N-and C-terminal ends of mKate2. This fragment was then substituted for the HA tag in the HA-AT 1 R fusions. All constructs were verified by DNA sequencing (University of Missouri).
Expression and purification of proteins
pET plasmids encoding biosensors and CaM were expressed in BL21(DE3) cells. Biosensors and CaM were purified as described in detail previously [25, 27] .
2.4. Screening for CaM-binding domains in AT 1 R using BSAT 1 R X Purified BSAT 1 R X were mixed at 22°C with titration buffer (25 mM Tris, 100 mM KCl, pH 7.5), 0.1 mg/mL bovine serum albumin and 1 mM CaCl 2 in a quartz cuvette (Hellma Analytics, Plainview, NY). Incremental purified CaM was added to the mixture as BSAT 1 R X fluorescence spectra were monitored in a QuantaMaster™-40 spectrofluorometer (Photon Technology International, Inc., Birmingham, NJ). Direct interaction between Ca 2+ -CaM and BSAT 1 R X insert was defined by disruption of FRET between ECFP and EYFP c , manifested as an increase in ECFP emission, a decrease in EYFP c emission and crossing of ECFP and EYFP c spectra at the isoemissive point (∼510 nm). BSAT 1 R X fractional responses were determined by the formula
where R min and R max are the ratios between emission intensities at λ475 and λ535 nm (F475/F535) when the biosensor is in unbound and maximally bound state, respectively. Dilution due to addition of CaM was minimal, yet was calculated using a detailed excel spreadsheet algorithm; however, the use of ratio in formula (1) negated the need to correct for dilution. Fractional biosensor responses were plotted against titrated CaM concentrations. Apparent K d values of BSAT 1 R X -CaM interactions were obtained by fitting fractional responses as a function of CaM concentration to a hyperbolic or quadratic binding equations as described [20, 27] :
where BS fract , [BS] and [CaM] are BSAT 1 R X fractional response, total concentration of BSAT 1 R X and CaM in the reaction mix, respectively. 
where, 1.6 is the in vitro K d value of XRhod-5F for Ca 2+ ; F min and F max are XRhod-5F emission intensities at λ600 nm under nominally Ca 2+ -free and Ca 2+ -saturating conditions, respectively. For indo-1, indicator responses were obtained as ratios between emission intensities at λ405 nm and λ485 nm, with excitation at λ340 nm. Free Ca 2+ values were calculated from these ratios using the formula 
where BS fract is obtained from Eq. (1); n is the Hill coefficient.
Cell isolation and culture
Primary VSMCs were isolated from descending section of porcine thoracic aortas based on a modification of the methods published by Bolzon, Ulrich-Merzenich and Leik as recently described [8, 13, 27, 29] . Descending porcine thoracic aortas were obtained fresh from a local slaughter house and transported in sterile phosphate buffered saline containing 3% penicillin/streptomycin. After removal of perivascular adipose tissue, the aortas were cut open and endothelial cells were removed by mechanical scraping and short incubation with 0.02% collagenase, 0.1% papain and 4 mM dithiothreitol and re-scraping. After rinsing in sterile PBS, the aortas were dissected into strips and the luminal surface was incubated with the enzyme mix for 90 min at 37°C. The luminal surface was subsequently scraped again, and cells from this treatment were grown in M-199 medium containing 10% fetal bovine medium and 2% penicillin/streptomycin in 90% humidified condition with 5% CO 2 at 37°C for one week. This approach consistently yields highly homologous populations of VSMCs, verified by both morphological features and smooth muscle α-actin expression. VSMCs were used for 2-3 passages after isolation. The protocol was approved by Des Moines University Institutional Biosafety Committee. Immortalized human embryonic kidney (HEK293) cells were purchased from ATCC (CRL-1573, initial passage 15) and cultured in DMEM medium containing and 10% fetal bovine serum. Cells were used for up to 15 passages from the initial stock from vendor.
Transfection
HEK293 cells were transfected with plasmids encoding mKate2 in isolation or fused with wild-type or mutant full-length AT 1 R using polyethylenimine (PEI) based on a modification of the method published by Aricescu et al. [2] . Briefly, HEK293 cells were grown to 60% confluency by the time of transfection. Plasmid DNA and PEI were allowed to form a complex at room temperature at a PEI:DNA mass ratio of 1.5:1 for 20 min in serum-free, antibiotic-free culture medium (DMEM or M-199). The cells were subsequently incubated with 1:5 vol/ vol DNA-PEI complex in DMEM containing 2% FBS for 6 h before medium was replaced by regular culture medium. The cells were cultured for another 12 h before experimentation.
Western blotting
All cell treatments were performed at room temperature in modified Tyrode's buffer (composition in mM: 150 NaCl, 2.7 KCl, 1.2 KH 2 PO 4 , 1.2 MgSO 4 , 10 HEPES, pH 7.5) containing 1.5 mM CaCl 2 . Following treatment and cell lysis, the protein content was measured using BCA assay performed in triplicate for all samples. All lanes in each gel were loaded with equal amounts of total proteins, adjusted for detectability with each antibody. After detection of the levels of ERK1/2 phosphorylation, the same membrane fragments were stripped and reprobed for total ERK1/2. Following secondary incubation, membrane fragments were developed using enhanced chemiluminescence in a ChemiDoc™ XRS + imaging system (Bio-Rad). Image Lab 5.0 software (Bio-Rad) was used for densitometry. Densitometric values of phosphorylated ERK1/2 bands were corrected for corresponding values of total ERK1/2 bands and normalized to control values.
Measurement of intracellular Ca
2+ concentration in HEK293 cells expressing mKate2-AT 1 R Intracellular Ca 2+ concentration was measured in HEK293 cells expressing mKate2 only or mKate2 in fusion with wild-type or mutant full-length AT 1 R as described previously [25, 26] . HEK293 cells were loaded with 4 μM fura-2/AM for 30 min in culture medium at 37°C. After removal of fura-2/AM, the cells were equilibrated in modified Tyrode's buffer (composition in mM: 150 NaCl, 2.7 KCl, 1.2 KH2PO 4 , 1.2 MgSO 4 , 10 HEPES, 1 CaCl 2 , pH 7.4) for 15 min at room temperature. mKate2 fluorescence was first identified and selected in RFP channel. Filter cube was then switched to fura-2 channel without changing the microscopic field. Excitation of fura-2 was alternated between λ340 nm and λ380 nm for 100 ms per 1-s cycle from an ultrahigh speed wavelength switcher (Lambda DG-4, Sutters Instruments) at 1-ms switching interval. Emission at λ510 nm was collected via an EMCCD camera (DU-885, Andor Technology). At the end of the agonistinduced Ca 2+ signal time course, R max values of fura-2 were obtained in all cells by adding 10 μM ionomycin and 10 mM CaCl 2 . R min values were determined in all cells using a previously developed equation [26] . Free Ca 2+ concentrations were calculated using the standard equation
where the K d value is 224 nM for fura-2; R is the observed fura-2 ratio during the experiments. S f and S b represent the emission intensities at λ510 nm corresponding to the Ca 2+ -free and Ca 2+ -bound states of fura-2. S b values were readily measured in all cells together with R max values. S f values were determined in each cell using a previously developed equation [26] .
Statistical analysis
Data were normally distributed and are expressed as means ± SD. Statistical analysis was performed using one-way ANOVA, followed by a Tukey post-hoc test. Statistical significance was set at P < 0.05.
Results
Screening for all CaM-binding domains in AT 1 R
The two known CaM-binding domains in AT 1 R include a.a. 215-232 in SMD3 and a.a. 305-327 in SMD4 JM [22, 32] . To confirm and screen for all CaM-binding sites on AT 1 R, we used a FRET-based approach to screen for CaM-binding sites in the submembrane domains of human AT 1 R. This method has allowed us to identify four distinct CaM-binding sites on the four submembrane domains of GPER, some of which do not conform to any known CaM-binding motifs [27] . We generated a host of FRET biosensors that consist of partial or full-length submembrane domains of AT 1 R flanked by the FRET donor ECFP and acceptor citrine EYFP (EYFP c ). These included BSAT 1 R 52-64 (covering SMD1), BSAT 1 R 125-141, (covering SMD2), BSAT 1 R 215-232 (covering previously identified CaM-binding domain in SMD3 [32] ), BSAT 1 R 215-242 (covering the entire SMD3), and a series of BSAT 1 R X to scan SMD4 due to the length of this domain (Table 1) . Fig. 1A -B recapitulate the principle of the biosensors for screening of CaM-binding sequences. A domain to be screened for CaM binding is inserted between EYFP c -ECFP (see also Section 2). In the absence of CaM interaction with the insert sequence, proximity between EYFP c and ECFP allows for robust FRET between them upon excitation of the ECFP moiety (430 nm) (Fig. 1A) . Specific interaction between CaM and the insert domain will disrupt FRET (Fig. 1B) , causing an increase in ECFP emission, a decrease in EYFP emission, and crossing of the emission spectra at the isoemissive point (∼510 nm) [27] . In the absence of specific binding with the insert, up to 700 μM CaM caused no emission spectral changes of the FRET pair [27] . With high sensitivity of FRET change in response to conformational changes of the insert upon CaM binding, it is easy to determine with high precision the apparent binding affinities between CaM and the insert domain in biosensor format. The length of the insert domain can be varied until the highest binding affinity is achieved, which identifies the correct domain required for full interaction with CaM. Fig. 1C shows a Coomassie gel of the biosensors characterized. Fig. 1D shows Coomassie staining of three separate preparations of CaM used to (Fig. 2D) . Since a.a. 215-232 only represents a portion of SMD3, we questioned if this represents the entire CaM-binding domain here. BSAT 1 R 215-242 , which covers the entire SMD3, clearly binds CaM (Fig. 2E) . However, BSAT 1 R 215-242 has a 3-fold higher affinity for Ca 2+ -CaM than BSAT 1 R 215-232 , indicating that full interaction with CaM requires the entire SMD3 (Fig. 2F ). Table 4 .
We previously described the parameter dynamic range (DR), determined as the maximal change in FRET ratio of the biosensors [27] . CaM causes significant conformational changes in its target proteins upon binding, a property important for its role in promoting target activities. The dynamic range of a BSAT 1 R X reflects the conformational changes of the insert domain that could occur upon interaction with CaM and provides a prediction of the potential conformational change that could take place in the holoreceptor upon CaM binding. Fig. 3A shows relative FRET ratios of the BSAT 1 [4, 5] . Fig. 4 shows the spectral changes of BSAT 1 R 125-141 , BSAT 1 R 215-242 , and BSAT 1 R 309-327 in response to Ca 2+ -saturated CaM (A, C, E) or apoCaM (B, D, F), at the concentrations that demonstrated maximal binding from the K d titrations (Fig. 2) . At CaM concentrations that produced maximal biosensor response in the presence of Ca 2+ , no response was observed in the absence of Ca 2+ (Fig. 4) . Ca 2+ dependency determined in the presence or absence of and BSAT 1 R 309-327 since its response range was the same with those of 
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the biosensors over the entire Ca 2+ titration. In these measurements, bleed-through artifacts were avoided by 1) alternate excitation of BSAT 1 R X and Ca 2+ indicator and 2) well separated excitation wavelengths of indo-1 (340 nm) or XRhod-5F (590 nm) from that of BSAT 1 R X (435 nm). To confirm absence of bleed-through artifacts using this approach for indo-1 and BSAT 1 R X , reactions were started with a mixture of indo-1 and BSAT 1 R 215-242 and 0.25 mM BAPTA in the absence of CaM. As incremental Ca 2+ was added, indo-1 ratio increased until saturation of the signal (Fig. 5B, upper panel) without any alteration in BSAT 1 R 215-242 ratio, which only increased upon addition of purified CaM (Fig. 5B, lower panel) . Similarly, absence of bleed-through artifacts was confirmed for XRhod-5F and BSAT 1 R X using the example of BSAT 1 R 125-141 (Fig. 5C ). Aggregate plot of BSAT 1 R X fractional saturations as a function of free Ca 2+ is shown in Fig. 5D . EC50(Ca 2+ ) values for the interactions are listed in (Table 4) .
CaM-AT 1 R interactions are required for AT 1 R-mediated ERK1/2 phosphorylation
The data presented so far show that AT 1 R possesses three distinct CaM-binding domains with disparate affinities and Ca 2+ sensitivities for their interactions with CaM. To initially assess the influence of CaM binding on AT 1 R-mediated signaling, we tested the effect of inhibiting CaM on AngII-induced ERK1/2 phosphorylation in primary VSMCs. We have routinely isolated primary vascular endothelial cells (PAECs) and then primary VSMCs from the same porcine aortas [25] [26] [27] . Under bright-field microscopy, isolated primary PAECs demonstrated typical cobble-stone morphology (Fig. 5A ) while the VSMCs demonstrated elongated morphology (Fig. 5B) . To confirm the smooth muscle nature of the VSMCs isolated, lysates from PAECs and VSMCs were immunoblotted for smooth muscle α-actin and β-actin. While β-actin was expressed in both lysates, smooth muscle α-actin was only detected in lysate from VSMCs (Fig. 5C ). Sub-confluent primary VSMCs were then pretreated for 30 min with vehicle, AT 1 R antagonist losartan (1 μM; IC 50 ∼ 5.5 nM), or the CaM antagonist W-7 (100 μM; K i ∼ 20 μM), followed by stimulation with 100 nM AngII for 5 min. AngII triggered robust increases in ERK1/2 phosphorylation. This effect was suppressed by losartan and abolished by W-7 pretreatment (Fig. 6) . The observed effect of W-7, while consistent with a role for CaM binding on AT 1 R-mediated signaling, can be non-specific. To assess the role of AT 1 R-CaM interaction at individual SMDs, we generated several Fig. 7A is presented as relative FRET ratio rather than fractional saturation as in Fig. 7B and C. Nevertheless, the available titration data clearly shows that BSAT 1 R 125-141mut has substantially reduced affinity for CaM compared to BSAT 1 R 125-141 . Fig. 7D-F show fractional responses of the wild-type vs mutant biosensors as a function of free Ca 2+ determined as described in Fig. 5A . All mutant biosensors showed reduced Ca 2+ sensitivities for interactions with CaM. The mutant SMD4 JM again exhibited a biphasic Ca 2+ response curve, similar to the wild-type version (Fig. 7F) . The apparent K d and EC50(Ca 2+ ) values for CaM interaction with the mutant biosensors are listed in Table 4 . Having confirmed the effects of the substitutions to decrease interactions with CaM at each domain, full-length AT 1 Rs with wild-type or mutant sequences at each SMD were tagged with a hemagglutinin (HA) epitope tag at their N termini and expressed in HEK293 cells. After 24 h, cells were serum starved for 4 h prior to treatment and lysis. Immunoblotting of samples with the anti-HA antibody showed equal expression levels of the expressed receptors and no bands recognized in the mock-transfected samples (lower immunoblots, Fig. 7G (i) , (ii), (iii)). Treatment of mock-transfected HEK293 cells with 100 nM AngII mildly increased ERK1/2 phosphorylation due to the activity of endogenous AT 1 R. Heterologous expression of wild-type AT 1 R substantially increased this effect. However, in cells expressing AT 1 R with the substitutions that were verified to reduce CaM-binding affinity and Ca 2+ sensitivities (Fig. 7A-F) in SMD2, SMD3, or SMD4 JM (upper blots, Fig. 7G , (i), (ii), or (iii), respectively) the effect of AngII was significantly reduced (Fig. 7G, iv) . Total ERK1/2 expression levels probed from the same membranes as for ERK1/2 phosphorylation were similar, indicating equal loading (middle blots, Fig. 7G (i) , (ii), (iii)).
CaM-AT 1 R interactions are important for AngII-induced Ca 2+ signals
To corroborate the results with AT 1 R-mediated ERK1/2 phosphorylation, we examined the effects of the CaM binding-reducing mutations in the individual SMDs on AngII-induced Ca 2+ signals. To guarantee Ca 2+ was measured in cells expressing wild-type or mutant AT 1 R, full-length AT 1 Rs with wild-type or mutant sequences were fused at their N termini with the fluorescence protein mKate2. N-terminal fusion was chosen to avoid potential interference of mKate2 with important binding partners at the submembrane domain level. HEK293 cells expressing plasmids encoding mKate2 alone or fused with wild-type or mutant AT 1 R were loaded with fura-2/AM for Ca 2+ imaging. mKate2 fluorescence was first identified and marked in the RFP channel (Fig. 8A) , followed by switching filter cube for imaging of fura-2 fluorescence in the same microscopic field (Fig. 8B) . This guaranteed that Ca 2+ signals were examined in cells expressing the intended AT 1 R version. Merged images (Fig. 8C) show high transfection efficiency. To allow correlation with EC50(Ca with mutant sequence on SMD2 (Fig. 8D) . To quantitate these signals, integrated areas under curve were calculated for the entire time courses (Fig. 8E) . AngII-induced Ca 2+ signals were significantly reduced in cells expressing mKate2 in fusion with AT 1 R containing CaM binding-reducing substitutions in SMD2, 3 or 4 (Fig. 8E) . Notably, in the case of AT 1 R with mutant SMD2 sequence, the AngII-induced Ca 2+ signal was very slow-rising and low amplitude, even compared to cells expressing only the mKate2 moiety ( Fig. 8D and E) . [16] .
What are the in-situ effects of multi-site CaM associations with AT 1 R? Kai et al. showed that synthetic peptides corresponding to residues 125-137 (rat sequence) in SMD2, 217-227 in the N-terminal side of SMD3, and 304-316 in SMD4 JM inhibit to various degrees AngIIinduced GTPase activity of isolated vascular smooth muscle membrane [9] . This indicates that these segments constitute, at least in part, G protein interaction sites for AT 1 R. Our data now show that the full SMD2 and SMD3, and a.a. 
